Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421404 · ClinicalTrials.gov registry record · Phase 2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
A Phase 2 study, sponsored by Priscilla Hsue, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04421404: Completed Phase 2 study, sponsored by Priscilla Hsue, MD.
NCT04421404 is a Phase 2 study that has completed, run by Priscilla Hsue, MD. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421404, a Phase 2 study, has completed, sponsored by Priscilla Hsue, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
Primary Outcome
Number of participants that progressed to mechanical ventilation or death within the first 14 days of enrollment.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL COVID-19 Convalescent Plasma (CCP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 2 |
What the finished NCT04421404 record still lists
NCT04421404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04421404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04421404 about?
NCT04421404 is a clinical study titled "Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients". The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
What is the current status of trial NCT04421404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-06-09. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT04421404?
The interventions under investigation include: Placebo (BIOLOGICAL), COVID-19 Convalescent Plasma (CCP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04421404?
This trial is sponsored by Priscilla Hsue, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04421404's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI